C530044N13Rik Inhibitors
Chemical inhibitors of C530044N13Rik can exert their effects through various mechanisms, impacting different signaling pathways within the cell. Wortmannin and LY294002, for instance, are direct inhibitors of phosphoinositide 3-kinases (PI3K), a family of enzymes involved in cellular functions such as growth, proliferation, and survival. By inhibiting PI3K, these chemicals can suppress the activity of downstream effectors that are critical for C530044N13Rik function. Rapamycin, by selectively inhibiting mammalian target of rapamycin (mTOR), can attenuate signaling pathways that are essential for the proper functioning of C530044N13Rik, while U0126 acts upon MEK1/2 in the MAPK/ERK pathway, potentially leading to a reduction in the activity of C530044N13Rik by suppressing the necessary upstream signals.
Further, SB203580 targets p38 MAPK, a key player in the cellular response to stress and inflammation, which could, in turn, affect the functional capacity of C530044N13Rik. PD98059 operates by selectively inhibiting MEK, impacting the ERK pathway and thus potentially disrupting the signaling processes on which C530044N13Rik relies. SP600125 inhibits JNK, part of the MAPK pathway, which could lead to the inhibition of gene expression and apoptosis processes necessary for C530044N13Rik activity. Src family kinases, which are inhibited by PP2, play a role in various cellular pathways, including those related to growth and differentiation, and their inhibition can also disrupt C530044N13Rik function. Additionally, Dasatinib and Imatinib Mesylate inhibit multiple tyrosine kinases, and their actions can thus alter a range of signaling pathways that are required for the functional activity of C530044N13Rik. Lastly, kinase inhibitors such as Sorafenib and Sunitinib target various tyrosine protein kinases, including VEGFR, PDGFR, and Raf kinases, thereby potentially impeding the pathways essential for the functioning of C530044N13Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways, including those regulating cell growth and survival. By inhibiting PI3K, wortmannin can lead to reduced activity of downstream effectors that may be critical for the function of C530044N13Rik, resulting in its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K. Given that PI3K signaling can regulate a variety of cellular processes, the inhibition by LY294002 can disrupt pathways that may be necessary for the proper function of C530044N13Rik, thereby inhibiting the protein's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is a central molecule in a signaling pathway involved in cell proliferation and survival. Inhibition of mTOR by rapamycin can attenuate the signaling required for C530044N13Rik function, indirectly leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes in the MAPK/ERK pathway. The MAPK/ERK pathway can regulate a wide array of cellular functions. By inhibiting MEK1/2, U0126 can suppress the pathway's signaling, potentially inhibiting the function of C530044N13Rik by disrupting signals that contribute to its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is implicated in stress responses and inflammation. Inhibition of p38 MAPK by SB203580 can lead to a reduction in the functional activity of cellular processes that might be necessary for C530044N13Rik function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which works upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can halt the phosphorylation and activation of ERK, thereby potentially inhibiting signaling processes that C530044N13Rik may rely on for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), part of the MAPK pathway. The JNK pathway is involved in controlling gene expression and apoptosis. Inhibition of JNK by SP600125 could disrupt cellular functions that are crucial for the activity of C530044N13Rik, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can influence multiple cellular pathways, including those involved in cell growth and differentiation. Inhibition of Src kinases by PP2 can disrupt signaling that C530044N13Rik might use, thereby inhibiting its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src kinases and BCR-ABL. By inhibiting these kinases, Dasatinib can alter signaling pathways that are possibly required for C530044N13Rik function, leading to its inhibition. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib Mesylate (Gleevec) is a selective inhibitor of certain tyrosine kinases including BCR-ABL and c-Kit. The inhibition of these kinases can modify signaling pathways that may be necessary for the functional activity of C530044N13Rik, resulting in its inhibition. | ||||||